Updates are available Correction dated 2025-07-24
Click to view Correction: https://doi.org/10.1038/s41467-025-62209-8
-
Authors
Hansen, Nikolaj Lervad
Kjaerulff, Louise https://orcid.org/0000-0001-6274-4265
Heck, Quinn Kalby https://orcid.org/0000-0001-5038-8152
Forman, Victor
Staerk, Dan https://orcid.org/0000-0003-0074-298X
Møller, Birger Lindberg https://orcid.org/0000-0002-3252-3119
Andersen-Ranberg, Johan https://orcid.org/0000-0002-6597-3431
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF18OC0031974, NNF20OC0061048, NNF16OC0021616)
Innovationsfonden (0160-00016B)
Lundbeckfonden (R223-2016-85)
- License Information
-
More Information
Article History
Received: 31 January 2022
Accepted: 11 August 2022
First Online: 25 August 2022
Change Date: 24 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-62209-8
Competing interests
: N.L.H., V.F., and J.A-R. are inventors of the patent entitled “Production of oxygenated diterpenoid compounds” (application number: PCT/EP2021/073656) related to the cytochrome P450 enzymes described in the paper. J.A-R. has established TriptoBIO to commercialize the patented technology. Other authors claim no competing interests.
